Drug Profile
Nitroxoline - Asieris Pharmaceuticals
Alternative Names: APL-1202; VesiqueLatest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Asieris Pharmaceuticals
- Class Antibacterials; Antifungals; Antineoplastics; Hydroxyquinolines; Quinolones; Small molecules
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Bladder cancer
- No development reported Prostate cancer
Most Recent Events
- 17 Apr 2024 Asieris Pharmaceuticals announces intention to submit clinical trial applications to the National Medical Products Administration (NMPA) for Bladder cancer
- 17 Apr 2024 Asieris Pharmaceuticals plans a clinical trials for Bladder cancer (Combination therapy, Second -line therapy or greater) in China
- 29 Jan 2024 Efficacy and adverse events data from the phase I/II ANTICIPATE trial in Bladder cancer released by Asieris Pharmaceuticals